What measures should be taken in the face of adverse reactions of Vigabatrin/vigabatrin

Although Vigabatrin/vigabatrin has unique advantages in the treatment of epilepsy, especially infantile spasms and refractory focal seizures, its adverse reactions also deserve great attention. The most common and controversial side effect is visual field loss, and symptoms such as drowsiness, fatigue, difficulty concentrating, weight gain, and abnormal behavior may also occur. In the face of these adverse reactions, it is crucial to adopt timely and effective management strategies.

Visual toxicity is one of the most serious side effects of vigabatrin. It is often manifested as progressive narrowing of the peripheral vision of both eyes, and in severe cases, it may even develop into tunnel vision. In order to prevent such problems, it is recommended that patients conduct a baseline visual field examination before taking the medication, and recheck the visual field every 3 to 6 months during the medication. Once an abnormality is detected, it should be immediately evaluated whether the drug needs to be discontinued to avoid irreversible optic nerve damage.

On the nervous system, Vigabatrin may cause drowsiness, dizziness, or abnormal behavior. Such adverse reactions are common at the beginning of medication or dose increase, and can usually be alleviated by lowering the initial dose, prolonging the dose adjustment time, or taking it in divided doses. If emotional instability or aggressive behavior occurs, you should communicate closely with a neurologist to evaluate whether the treatment plan needs to be adjusted or combined with psychiatric drug management.

Some patients, especially children, experience metabolic side effects such as weight gain or sodium and water retention while taking vigabatrin. It is recommended to cooperate with dietary management and regular weight monitoring, and provide nutritional guidance when necessary.

In addition, vigabatrin can cause reversible MRI brain white matter changes in a small number of patients. MRI brain white matter changes are mostly observed in infants and young children. Most of these changes are asymptomatic, but if combined with neurological deterioration, imaging evaluation should be carried out as soon as possible and drug discontinuation should be considered.

Reference materials:https://www.sabril.net/